Hebei Changshan Biochem Pharma and Albumedix enter into agreement for development of patient-friendly type II diabetes treatment
Albumedix albumin-based half-life extension technology used in clinical development of Hebei Changshan Biochem Pharma’s once-weekly diabetes treatment for the Chinese market.
Albumedix and Hebei Changshan Biochem Pharma (Changshan) have entered into a supply agreement for the development of a novel type II diabetes treatment that enables once-weekly dosing. The agreement will see Albumedix’s recombinant albumin based half-life extension platform used for the development and later commercialization of a modified glucagon-like-peptide albumin conjugate (Albenatide) for the treatment of patients living with the condition in China.
According to the International Diabetes Federation, the Chinese diabetes population amounts to a staggering 114 million, representing a third of all people who have the condition worldwide. With a diabetes prevalence of 11.6 % for adults, China officially has the world’s largest diabetes epidemic. By combining Albumedix’s albumin-based drug delivery technology with Changshan’s clinical development expertise, Albenatide has the potential to extend the dosing frequency required by diabetics from daily to weekly, thereby significantly improving patient quality of life and treatment adherence, as well as overall treatment cost.
Changshan operates through a joint venture with Los Angeles based ConjuChem, for the development of long-acting diabetic treatments. “The collaboration between ConjuChem and Changshan is focused on the development of diabetes therapies for the Chinese market and we are currently in a Phase I clinical trial with Albenatide, with the aim of moving into phase II later this year,” said Dr Patrick Soon-Shiong, Chairman and CEO, ConjuChem, LLC and NantWorks, LLC. “ConjuChem created the Drug Affinity Complex (DACTM) which uses recombinant human albumin to improve a drug’s therapeutic index. We are confident that working with Albumedix and its exciting albumin-based platform will enable us to reach our goal of developing a patient friendly, once-weekly diabetes treatment.”
“China currently has the largest diabetes population in the world. Through the collaborations with ConjuChem and Albumedix, we are confident that we will be able to develop a more efficacious, safer and easier to use anti-diabetes medicine which will be a significant benefit to Chinese patients,” said Mr Shuhua Gao, Chairman and General Manager of Changshan Biochem Pharma.
Albumedix’s albumin-based drug delivery platform, known as VELTIS, is a platform of native and engineered recombinant human albumins. When combined with a drug candidate, it offers the potential for adaptive control of therapeutic half-life. The platform can significantly improve the treatment options available to diabetes patients by maintaining the therapeutic activity for prolonged periods, opening the door towards extended dosing intervals and improved quality of life.
“The adoption of Albumedix recombinant albumin products by Changshan is yet another example of how our albumin-based solutions can help alleviate some of the many complications faced daily by patients living with chronic diseases such as diabetes,” comments Peter Rosholm, CEO, Albumedix.
This agreement comes only a few months after the US market authorization of CSL Behring’s Idelvion, a once-every-14-day hemophilia B treatment, which also utilizes Albumedix’s albumin-based technology.
“Like Idelvion, Albenatide further demonstrates the clinical and market value of our albumin-based platform,” adds Peter Rosholm.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance